Skip to main content

Table 2 Results of clinical trials using MSCs to prevent GVHD

From: Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: a systematic review

Clinical trial

Median age(range)

MSC frequency

MSC dosage

aGVHD morbidity (%)

cGVHD morbidity (%)

Survival rate (%)

Follow-up time

References

No.21

Standard prophylaxis group:30y (18–60) Standard prophylaxis + MSCs group:37y (20–63)

1

1 × 106/kg

100d grade II–IV aGVHD:Standard prophylaxis group:29.4 Standard prophylaxis + MSCs group:9.4 p = 0.041

N/A

exact time unknown:Standard prophylaxis group:61.8 Standard prophylaxis + MSCs group:81.2 p < 0.05

N/A

Kuzmina et al. [42]

No.21

34y (17–63)

1

1.2 (0.9–1.65) × 106/kg

100d grade II–IV aGVHD:Standard prophylaxis group:20.5 Standard prophylaxis + MSCs group:10.2

N/A

N/A

N/A

Shipounova et al. [43]

No.34

MSC group:58y (21–69) historic group:55y (10–69)

1

N/A

100d grade II–IV aGVHD:MSC group:35 historic group:56 grade IV aGVHD:MSC group:10 historic group:19

1y moderate/severe cGVHD:MSC group:65

1y:MSC group:80 historic group:44 p = 0.02

560d

Baron et al. [93]

No.38

MSC group:6.9y (3.3–12.5) historic group:9.5y (8.4–18.7)

1

1/5 × 106/kg

grade I–II aGVHD:MSC group:57.1 historic group:62.5 p = 0.83 grade III–IV aGVHD:MSC group:14.3 historic group:0 p = 0.36

extensive cGVHD:MSC group:14.3 historic group:50.0 p = 0.27

2y:MSC group:85.7 historic group:55.6 p = 0.15

N/A

Lee et al. [94]

No.60

N/A

3.7 (2–4)

3 × 107/100 mL/m

N/A

2y:MSC group:27.4 control group:49.0 p = 0.021

2y:MSC group:66.1 historic group:61.3 p > 0.05

51m

Gao et al. [92]

  1. d represents days; w represents weeks; y represents years